• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Medivir

1.68 SEK

-3.44 %

Less than 1K followers

MVIR

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
-3.44 %
-16.11 %
-29.92 %
+311.25 %
+336.88 %
+2.56 %
-71.86 %
-74.84 %
-97.13 %

Medivir develops drugs with a focus on cancer diseases where the medical needs are great. The drug candidates are directed towards indication areas where available treatment methods are limited or absent. Medivir focuses on the development of fostrox, a drug candidate that has been designed to selectively treat cancer cells in the liver. The company was founded in 1988 and is headquartered in Huddinge.

Read more
Market cap
1.04B SEK
Turnover
2.68M SEK
Revenue
8.5M
EBIT %
-1,089.41 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
EPS and dividend
Financial calendar
All
Webcasts
Press releases
3rd party
ShowingAll content types

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
20/7
2026

Extraordinary general meeting '26

20/8
2026

Interim report Q2'26

5/11
2026

Interim report Q3'26

Regulatory press release2026-06-25 15:34

Finansinspektionen: Flaggningsmeddelande i Medivir Aktiebolag

Medivir
Regulatory press release2026-06-25 09:15

Finansinspektionen: Flaggningsmeddelande i Medivir Aktiebolag

Medivir
Regulatory press release2026-06-22 09:31

Medivir offentliggör informationsdokument för upptagande till handel av aktier på Nasdaq Stockholm

Medivir

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release2026-06-22 09:31

Medivir Publishes disclosure document for the admission to trading of shares on Nasdaq Stockholm

Medivir
Press release2026-06-18 12:41

DNB Carnegie Access: Medivir: Withdrawing fair value range

Medivir
Regulatory press release2026-06-17 22:30

Kallelse till extra bolagsstämma i Medivir AB (publ)

Medivir
Regulatory press release2026-06-17 22:30

Notice of Extraordinary General Meeting of Medivir AB (publ)

Medivir
Regulatory press release2026-06-17 22:25

Medivir har genomfört en riktad nyemission om cirka 140 MSEK

Medivir
Regulatory press release2026-06-17 22:25

Medivir has completed a directed share issue of approximately SEK 140 million

Medivir
Regulatory press release2026-06-17 17:31

Medivir offentliggör avsikt att genomföra en riktad nyemission om cirka 130 MSEK

Medivir
Regulatory press release2026-06-17 17:31

Medivir announces intention to carry out a directed share issue of approximately SEK 130 million

Medivir
Press release2026-06-09 16:00

Positiva resultat med fostrox + lenvatinib publicerade i Clinical Cancer Research

Medivir
Press release2026-06-09 16:00

Positive results for fostrox + lenvatinib published in Clinical Cancer Research

Medivir
Press release2026-06-02 09:20

DNB Carnegie Access: Medivir: Reflections from ASCO 2026 with a focus on HCC

Medivir
Regulatory press release2026-05-21 09:00

Medivir meddelar att första patienten har inkluderats i FLEX-HCC-studien

Medivir
Regulatory press release2026-05-21 09:00

Medivir announces first patient enrolled in FLEX-HCC study

Medivir
Press release2026-05-12 12:45

DNB Carnegie Access: Medivir – Ett starkare bolag

Medivir
Regulatory press release2026-05-07 16:00

Beslut vid årsstämma i Medivir den 7 maj 2026

Medivir
Regulatory press release2026-05-07 16:00

Resolutions at the Annual General Meeting in Medivir on 7 May 2026

Medivir
Press release2026-05-07 07:09

DNB Carnegie Access: Medivir: Equity story improving on pipeline breadth and financing

Medivir